Bisphosphonates in preclinical bone oncology

Bisphosphonates in preclinical bone oncology,10.1016/j.bone.2010.11.017,Bone,Philippe Clézardin,Ismahène Benzaïd,Peter I. Croucher

Bisphosphonates in preclinical bone oncology   (Citations: 1)
BibTex | RIS | RefWorks Download
Bisphosphonates, especially nitrogen-containing bisphosphonates, are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that nitrogen-containing bisphosphonates exert direct and indirect anticancer activities through inhibition of tumor cell functions, enhancement of the cytotoxic activity of chemotherapy agents, inhibition of tumor angiogenesis, and stimulation of antitumor immune reactions. This review examines the current evidence and provides insights into ongoing preclinical research on anticancer activities of these bisphosphonates in animal models of tumorigenesis and metastasis.This article is part of a Special Issue entitled Bisphosphonates.
Journal: Bone , vol. 49, no. 1, pp. 66-70, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: